Deamidation is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-30. Numbers and descriptions here follow the published literature rather than marketing material.
Verification of research-grade material involves comparing a supplier chromatogram against an in-house reference, checking the observed mass against the calculated value, and where possible confirming residue order by tandem mass spectrometry or enzymatic peptide mapping. Purity claims should be read alongside the method used to obtain them, because detection wavelength and integration settings alter the result. Batch-specific data, rather than a generic grade statement, is the informative part of a certificate.
Identity and purity of epitalon samples are normally established by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, combined with mass spectrometry. The mass spectrum confirms the expected molecular ion and can reveal truncated or oxidised by-products. Amino acid analysis after acid hydrolysis verifies that the four residues are present in the expected ratio. Certificates typically report a purity figure taken from chromatographic peak area, expressed as a percentage of total integrated signal.
The compound is described in the literature as a derivative of epithalamin, a preparation obtained from bovine pineal tissue. Work on this peptide family was carried out mainly by a research group in Saint Petersburg beginning in the 1980s, and the substance was later registered for clinical use in Russia under the name Epitalon. Outside that region it is generally treated as a research chemical rather than an approved medicine. Statements about its biological activity rest on a relatively small number of studies, and independent replication remains limited.
In its supplied form epitalon is a white to off-white powder, usually lyophilized and often hygroscopic. It dissolves readily in water and in aqueous buffers, and it is commonly handled as the acetate or trifluoroacetate salt to improve stability during purification and drying. The amide backbone is labile in aqueous media, so solutions are less durable than the dry solid. Handling notes in the chemical literature therefore emphasize keeping the powder dry, cool and shielded from light until it is dissolved.
Epitalon is a synthetic tetrapeptide whose sequence is alanine-glutamate-aspartate-glycine, written in single-letter code as AEDG. The four residues are joined by three peptide bonds, giving a linear backbone with no branching and no disulfide bridges. Its calculated molecular mass for the free form is approximately 390.3 daltons, a figure that rises when the compound is supplied as an acetate or trifluoroacetate salt. Because the chain is short, the molecule is defined entirely by its residue order rather than by any folded three-dimensional structure.
| Property | Value | Notes |
|---|---|---|
| Typical purity specification | 95 percent or higher by HPLC area | Higher grades are also offered |
| Primary analytical method | Reversed-phase HPLC, UV detection | Frequently paired with mass spectrometry |
| Confirmatory technique | Electrospray mass spectrometry | Observed mass compared with theory |
| Storage temperature | Minus 20 degrees Celsius, dry powder | Sealed, desiccated, protected from light |
| Solution handling | Prepare fresh before use | Hydrolysis proceeds in aqueous media |
Laboratory handling begins with dissolution of the lyophilized powder in water or a suitable aqueous buffer. The dry solid is the more stable form, so stock solutions are generally prepared only when required and kept cold afterwards. Repeated freezing and thawing of a solution is avoided because it encourages aggregation and gradual loss of the intact chain. Diluents and containers are selected to limit adsorption of a short peptide onto plastic surfaces and to reduce microbial growth in aqueous preparations.
Stability depends strongly on pH, temperature and the presence of oxygen and trace metals. Cleavage of the backbone proceeds faster under neutral to alkaline conditions, whereas acidic solutions tend to slow that reaction. The aspartate and glutamate side chains can undergo deamidation or imide formation over time, generating closely related impurities. Published stability data specific to epitalon are sparse, so the usable life of a given solution is best regarded as an open question that depends on buffer composition, concentration and storage temperature.
Proposed mechanisms centre on cell-culture observations rather than a defined receptor interaction. Several reports describe increased expression of the telomerase catalytic subunit after exposure of cultured human cells, and the authors attributed the effect to short peptide fragments entering the nucleus and influencing gene transcription. No receptor for the tetrapeptide has been identified, and the free peptide is expected to be degraded rapidly by plasma peptidases. Whether any measurable fraction reaches intact tissues after administration remains an unresolved question rather than an established finding.
The published literature is dominated by a small number of research groups, much of it in Russian-language journals, and independent replication outside those groups is limited. Studies are typically small, use cultured cells or rodent models, and report endpoints that differ between papers, which makes comparison difficult. Large randomised human trials have not appeared in the indexed literature. Questions about absorption, distribution and clearance are therefore still treated as open in reviews that mention the compound.
Epitalon is a synthetic tetrapeptide with the sequence alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. Its design traces to epithalamin, a peptide fraction prepared from bovine pineal gland extracts that researchers in Saint Petersburg began investigating in the 1970s. The compound has a molecular formula of C14H22N4O9 and a nominal molecular mass near 390 daltons. It holds no approved drug status in the United States or the European Union, and material sold under this name is generally offered as a research chemical rather than a finished pharmaceutical product.
Identity testing for epitalon relies on reversed-phase high-performance liquid chromatography for purity and mass spectrometry for mass confirmation. Because the sequence contains no tryptophan or tyrosine, ultraviolet detection at 280 nanometres is insensitive, so chromatographic methods usually monitor absorbance near 214 nanometres, where the peptide backbone absorbs. Electrospray ionisation or matrix-assisted laser desorption/ionisation then checks the intact mass against the expected value near 390 daltons. Peptide mapping or amino acid analysis after acid hydrolysis can supplement these measurements, although such confirmatory work is seldom reported on commercial certificates of analysis.
Stability of the tetrapeptide follows ordinary peptide chemistry rather than any unusual structural feature. The aspartate-glycine pair is prone to aspartimide formation under mildly basic or neutral conditions, and deamidation can follow, altering both mass and chromatographic retention. Dry lyophilised powder kept at or below minus twenty degrees Celsius is the usual handling recommendation, with repeated freeze-thaw cycles avoided. Once dissolved in neutral aqueous buffer, degradation proceeds over days to weeks depending on pH and temperature, while acidic conditions generally slow the aspartimide route. A formal stability-indicating study has not been published in the indexed literature.
Because epitalon has no pharmacopoeial monograph, quality assessment depends on supplier documentation and independent testing. Certificates of analysis typically report a purity figure from a single chromatographic run, a measured mass and sometimes an appearance description, but methods and acceptance criteria are not harmonised across vendors. Third-party laboratories can repeat identity and purity measurements, and mismatches between labelled and measured peptide content have been described for research peptides generally. What constitutes adequate identity confirmation for a molecule of this size stays an open question, since mass agreement alone does not separate closely related sequences.
== Simulation == In addition to experimental investigation of graphene and graphene-based devices, numerical modeling and simulation of graphene has also been an important research topic. The Kubo formula provides an analytic expression for the graphene's conductivity and shows that it is a function of several physical parameters including wavelength, temperature, and chemical potential. Moreover, a surface conductivity model, which describes graphene as an infinitesimally thin (two-sided) sheet with a local and isotropic conductivity, has been proposed. This model permits the derivation of analytical expressions for the electromagnetic field in the presence of a graphene sheet in terms of a dyadic Green function (represented using Sommerfeld integrals) and exciting electric current. Even though these analytical models and methods can provide results for several canonical problems for benchmarking purposes, many practical problems involving graphene, such as the design of arbitrarily shaped electromagnetic devices, are analytically intractable. With the recent advances in the field of computational electromagnetics (CEM), various accurate and efficient numerical methods have become available for analysis of electromagnetic field/wave interactions on graphene sheets and/or graphene-based devices. A comprehensive summary of computational tools developed for analyzing graphene-based devices/systems is proposed.
== History and etymology == Discovered by Tillett and Francis in 1930, it was initially thought that CRP might be a pathogenic secretion since it was elevated in a variety of illnesses, including cancer. The later discovery of hepatic synthesis (made in the liver) demonstrated that it is a native protein. Initially, CRP was measured using the quellung reaction which gave a positive or a negative result. More precise methods nowadays use dynamic light scattering after reaction with CRP-specific antibodies. CRP was so named because it was first identified as a substance in the serum of patients with acute inflammation that reacted with the cell wall polysaccharide (C-polysaccharide) of pneumococcus.
== Nomenclature == Signal peptides are not to be confused with the leader peptides sometimes encoded by leader mRNA, although both are sometimes ambiguously referred to as "leader peptides." These other leader peptides are short polypeptides that do not function in protein localization, but instead may regulate transcription or translation of the main protein, and are not part of the final protein sequence. This type of leader peptide primarily refers to a form of gene regulation found in bacteria, although a similar mechanism is used to regulate eukaryotic genes, which is referred to as uORFs (upstream open reading frames).
=== Role in cancer progression and therapy resistance === ITGA1 contributes to tumor progression by regulating survival, migration, invasion, and resistance to anticancer therapies. In Pancreatic Ductal Adenocarcinoma (PDAC), ITGA1-mediated collagen EMT signaling promotes the survival of mesenchymal tumor cell populations, metastatic dissemination, and resistance to gemcitabine treatment. Inhibition of ITGA1 increases sensitivity to chemotherapy, making treatment more effective and supporting its capacity as a potential therapeutic target. In glioma, ITGA1 contributes to temozolomide (TMZ) resistance by activating the PI3K/AKT/Bcl-2 signaling pathway. Increased ITGA1 activity promotes anti-apoptotic signaling which prevents tumor cells from apoptosizing therefore leading to survival of tumor cells. Suppressing ITGA1 increases apoptosis and improves TMZ sensitivity. ITGA1 expression in glioma is regulated by the hsa-miR01298-5p pathway, which directly binds the ITGA1 3' untranslated region to suppress ITGA1 expression. Increased ITGA1 reverses those effects, making resistance to chemotherapy more likely.
Sources: en.wikipedia.org
The emergent long elimination timescale appears because not only is the intrinsic degradation time scale an order of magnitude longer than that of binding, but also because the endosomal antibody concentration is low due to high binding affinity. In particular, the analysis shows that clearance in the terminal phase is inherently nonlinear, with clearance,
Pat Striker (パトストライカー, Pato Sutoraikā): Deka Red's personal six-wheeled, police car-themed Deka Machine that forms the head and torso of Dekaranger Robo. It is also equipped with a pair of Striker Arms (ストライカーアーム, Sutoraikā Āmu), which allows it to wield the Judgement Sword (ジャッジメントソード, Jajjimento Sōdo) in its Driving Sword (ドライビングソード, Doraibingu Sōdo) formation. Pat Gyrer (パトジャイラー, Pato Jairā): Deka Blue's personal autogyro-themed Deka Machine that forms the left leg of Dekaranger Robo. It is also equipped with the Gyro Vulcan (ジャイロバルカン, Jairo Barukan) Gatling guns, the Gyro Wapper (ジャイロワッパー, Jairo Wappā) handcuffs, and the Magnet Wire (マグネワイヤー, Magune Waiyā). PaTrailer (パトレーラー, Patorērā): Deka Green's personal armored semi-trailer truck-themed Deka Machine that forms the right leg of Dekaranger Robo. It also carries the Judgement Sword and the Signal Cannon (シグナルキャノン, Shigunaru Kyanon) into battle. Pat Armor (パトアーマー, Pato Āmā): Deka Yellow's personal armored car-themed Deka Machine that forms the right arm of Dekaranger Robo. It is also equipped with floodlights, which allow it to perform the Armor Attack (アーマーアタック, Āmā Atakku) and Light Flash (ライトフラッシュ, Raito Furasshu) attacks. Pat Signer (パトシグナー, Pato Shigunā): Deka Pink's personal buggy-themed Deka Machine that forms the left arm of Dekaranger Robo. It is also equipped with a large retractable signboard.
=== Controversy === In 2010, Novo Nordisk breached the Association of the British Pharmaceutical Industry's code of conduct by failing to provide information about side effects, and by promoting it prior to being granted market authorization. In 2012, the non-profit consumer advocacy group Public Citizen petitioned the US Food and Drug Administration (FDA) to immediately remove liraglutide from the market because they concluded that risks of thyroid cancer and pancreatitis outweigh any documented benefits. In 2017, Novo Nordisk agreed to pay $58.65 million to settle multiple whistleblower lawsuits alleging that the company had illegally marketed, promoted, and sold Victoza for off-label uses (such as for type 1 diabetes) in violation of the Federal Food, Drug, and Cosmetic Act and the False Claims Act. Novo Nordisk paid an additional $1.45 million to the states of California and Illinois to settle whistleblower cases alleging fraud against private commercial health insurers.
Sources: en.wikipedia.org
The usual approach is reversed-phase HPLC with ultraviolet detection, reported as a percentage of total peak area. Mass spectrometry is used alongside chromatography to confirm identity rather than purity alone.
The dry powder is commonly kept at minus twenty degrees Celsius, desiccated and away from light. Solutions are generally prepared fresh because they break down faster than the solid form.
Tandem mass spectrometry or enzymatic peptide mapping can establish residue order. A single intact mass value indicates composition and molecular weight but not always the precise arrangement of residues.
The peptide contains four residues in the order alanine, glutamate, aspartate and glycine, abbreviated AEDG. The chain is linear and held together by three peptide bonds. Its calculated mass for the uncharged free form is about 390.3 daltons.